Estimating treatment effects with treatment switching via semicompeting risks models: An application to a colorectal cancer study

Biometrika

Volumn 99, Issue 1, 2012, Pages 167-184

  Zeng, Donglin ^a   Chen, Qingxia ^b   Chen, Ming Hui ^c   Ibrahim, Joseph G ^a,d  

^a University of North Carolina at Chapel Hill   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d AMGEN INC   (United States)

Author keywords

Expectation maximization algorithm; Maximum likelihood estimate; Noncompliance; Panitumumab; Partial switching; Transition model; Treatment switching

Indexed keywords

EID: 84863237618     PISSN: 00063444     EISSN: 14643510     Source Type: Journal    
DOI: 10.1093/biomet/asr062     Document Type: Article

References (27)

1. AMADO, R. G., WOLF, M., PEETERS, M., CUTSEM, E. V., SIENA, S., FREEMAN, D. J., JUAN, T., SIKORSKI, R., SUGGS, S., RADINSKY, R., et al. (2008).Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 1626-34.
2. BARTHEL, F. M. S., BABIKER, A., ROYSTON, P. & PARMAR, M. K. B. (2006). Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over. Statist. Med. 25, 2521-42. (Pubitemid 44082444)
3. BRANSON, M. & WHITEHEAD, J. (2002). Estimating a treatment effect in survival studies in which patients switch treatment. Statist. Med. 21, 2449-63. (Pubitemid 34960010)
4. FIX, E. & NEYMAN, J. (1951). A simple stochastic model of recovery, relapse, death and loss of patients. Hum. Biol. 23, 205-41.
5. GREENLAND, S., LANES, S. & JARA, M. (2008). Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and g-estimation. Clin. Trials 5, 5-13. (Pubitemid 351412366)
6. HERNÁ N, M. Á ., BRUMBACK, B. & ROBINS, J. M. (2000). Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11, 561-70. (Pubitemid 30660035)
7. JIANG, Q., SNAPINN, S. M. & IGLEWICZ, B. (2004). Calculation of sample size in endpoint trials: the impact of informative noncompliance. Biometrics 60, 800-6. (Pubitemid 39181126)
8. LACHIN, J. M. & FOULKES, M. A. (1986). Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 42, 507-19.
9. LAKATOS, E. (1988). Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 44, 229-41. (Pubitemid 18098824)
10. LARSON, G. & DINSE, G. (1985). A mixture model for the regression analysis of competing risks data. Appl. Statist. 34, 201-11. (Pubitemid 16478808)
11. LAW, M. G. & KALDOR, J. M. (1996). Survival analyses of randomized trials adjusting for patients who switch treatments. Statist. Med. 15, 2069-76. (Pubitemid 26332298)
12. LONDON, W. B., FRANTZ, C. N., CAMPBELL, L. A., SEEGER, R. C., BRUMBACK, B. A., COHN, S. L., MATTHAY, K. K., CASTLEBERRY, R. P. & DILLER, L. (2010). Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a children's oncology group study. J. Clin. Oncol. 28, 3808-15.
13. LOUIS, T. A. (1982). Finding the observed information matrix when using the EM algorithm. J. R. Statist. Soc. B 13, 2233-47.
14. LU, J. & PAJAK, T. F. (2000). Statistical power for a long-term survival trial with a time-dependent treatment effect. Contr. Clin. Trials 21, 561-73. (Pubitemid 32056219)
15. LUNCEFORD, J. K., DAVIDIAN, M. & TSIATIS, A. A. (2002). Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials. Biometrics 58, 48-57. (Pubitemid 34194487)
16. MARCUS, S. M. & GIBBONS, R. D. (2001). Estimating the efficacy of receiving treatment in randomized clinical trials with noncompliance. Health Serv. Outcomes Res. Methodol. 2, 247-58. (Pubitemid 35153451)
17. PORCHER, R., ĹEVY, V. & CHEVRET, S. (2002). Sample size correction for treatment crossovers in randomized clinical trials with a survival endpoint. Contr. Clin. Trials 23, 650-61. (Pubitemid 36005475)
18. ROBINS, J. M. & TSIATIS, A. A. (1991). Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun. Statist. A 20, 2609-31.
19. ROBINS, J.M., HERNÁ N, M. Á . & BRUMBACK, B. (2000).Marginal structural models and causal inference in epidemiology. Epidemiology 11, 550-60. (Pubitemid 30660034)
20. SHAO, J., CHANG, M. & CHOW, S.-C. (2005). Statistical inference for cancer trials with treatment switching. Statist. Med. 24, 1783-90. (Pubitemid 40872642)
21. SVERDRUP, E. (1965). Estimates and test procedures in connection with stochastic models for deaths, recoveries and transfersb etween differents tates of health. Skand. Aktuar. 52, 185-211.
22. VAN DER VAART, A. W. & WELLNER, J. A. (1996). Weak Convergence and Empirical Processes. New York: Springer.
23. WHITE, I. R. (1997). Editorial on survival analyses of randomized trials adjusting for patients who switch treatments by M. G. Law and J. M. Kaldor. Statist. Med. 16, 2619-25.
24. WHITE, I. R. (2006). Letter to the editor. Estimating treatment effects in randomized trials with treatment switching. Statist. Med. 25, 1619-22.
25. WHITE, I. R., CARPENTER, J., POCOCK, S. J. & HENDERSON, R. A. (2003). Adjusting treatment comparisons to account for non-randomized interventions: an example from an angina trial. Statist. Med. 22, 781-93. (Pubitemid 36266966)
26. YAMAGUCHI, T.&OHASHI, Y. (2004).Adjusting for differential proportions of second-line treatment in cancer clinicals trials. Part II: an application in a clinical trial of unresectable non-small-cell lung cancer. Statist. Med. 23, 2005-22. (Pubitemid 38968025)
27. ZENG, D. & LIN, D. Y. (2010). A general asymptotic theory for maximum likelihood estimation in semiparametric regression models with censored data. Statist. Sinica 20, 871-910.